The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Involvement of IL–6 in the pathogenesis of inflammatory bowel disease and colon cancer
Abstract
Inflammatory bowel disease (IBD), which consists of Crohn's disease and ulcerative colitis, is defined as a chronic inflammation of the gastrointestinal tract. The etiopathogenetic mechanisms underlying the development of IBD are still not completely understood, and the therapeutic strategies used thus far have been limited to mostly evidence-based principles. There is growing evidence that the pro-inflammatory cytokine interleukin (IL)-6 plays a crucial part in the uncontrolled intestinal inflammatory process, which is a main characteristic of IBD. There is elevated production of IL-6 and its soluble receptor (sIL-6R) by intestinal macrophages and CD4+T-cells. The increased formation of IL-6-sIL-6R complexes that interact with gp130 on the membrane of CD4+T-cells (trans-signaling) lead to an increased expression and nuclear translocation of STAT3, which causes the induction of anti-apoptotic genes, such as Bcl-xl. This leads to an augmented resistance of lamina propria T-cells to apoptosis. The ensuing T-cell expansion contributes to the perpetuation of chronic intestinal inflammation. This understanding concerning the predominant pathogenic role of an IL-6-dependent inflammatory cascade may lead to the development of new therapeutic strategies in the treatment of this disease. Recent studies have also suggested a potential role of IL-6-sIL-6R in the pathogenesis of colon cancer and, therefore, imply a possible novel therapeutic strategy targeting the sIL-6R and ensuing IL-6 trans-signaling.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, IL-6 production may enhance mucosal inflammation via T cell activation,6,35,36 providing a link between inflammation and tumour growth.”
From PU.1-driven Th9 Cells Promote Colorectal Cancer in Experimental Colitis Models Through Il-6 Effects in Intestinal Epithelial Cells (2022) · cites this paper as [35]
Citations
Cites
Podolsky, D. K. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020831 · Cited by 3,183
The risk of colorectal cancer in ulcerative colitis: a meta-analysis
Eaden, J., Abrams, K. R., & Mayberry, J. F. (2001) · Gut · doi:10.1136/gut.48.4.526 · Cited by 2,948
Inflammatory bowel disease: Etiology and pathogenesis
Fiocchi, C. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70381-6 · Cited by 2,059
Ulcerative Colitis and Colorectal Cancer
Ekbom, A., Helmick, C. G., Zack, M. M., & Adami, H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011013231802 · Cited by 1,794
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130
Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T., & Kishimoto, T. (1989) · Cell · doi:10.1016/0092-8674(89)90438-8 · Cited by 1,396
Antibodies to interleukin 12 abrogate established experimental colitis in mice.
Neurath, M., Fuss, I. J., Kelsall, B. L., Stuber, E. R., & Strober, W. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.182.5.1281 · Cited by 1,334
Self-citationAtreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., et al. (2000) · Nature Medicine · doi:10.1038/75068 · Cited by 1,293
Self-citationFuss, I. J., Neurath, M. F., Boirivant, M., Klein, J. S., de la Motte, C., Strong, S. A., Fiocchi, C., & Strober, W. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.3.1261 · Cited by 1,227
Self-citationPodolsky, D. K. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109263251306 · Cited by 1,226
Flagged first, then by citations
Cited by
Sorted by citations
Terzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.058 · Cited by 1,974
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers
Yao, X., Huang, J., Zhong, H., Shen, N., Faggioni, R., Fung, M. S. C., & Yao, Y. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.004 · Cited by 677
Guihard, P. J., Danger, Y., Royer, B. B.-L., David, E., Brion, R., Delécrin, J., Richards, C. D., Chevalier, S., Rédiní, F., Heymann, D., et al. (2012) · Stem Cells · doi:10.1002/stem.1040 · Cited by 477
Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage
Grivennikov, S. I., & Karin, M. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.140145 · Cited by 560
Metadata
- Authors
- Atreya, R., & Neurath, M. F.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- Corresponding author
- Neurath, Markus F.
- Venue
- Clinical Reviews in Allergy & Immunology
- Published
- 2005
- Volume
- 28
- Issue
- 3
- Pages
- 187-196
- ISSN
- 1080-0549 (ISSN-L)
- OpenAlex
- W2024255214
- Cited by
- 324
- References
- 57
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 21 · 2023: 23 · 2022: 22 · 2021: 25 · 2020: 22 · 2019: 9 · 2018: 17 · 2017: 13 · 2016: 20 · 2015: 13 · 2014: 13 · 2013: 13 · 2012: 12
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Reviews in Allergy & Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- interleukin-6, inflammatory bowel disease, Crohn's disease, ulcerative colitis, colon cancer, soluble IL-6 receptor, IL-6 trans-signaling, gp130, STAT3, Bcl-xL, T cell apoptosis, intestinal inflammation, CD4+ T cells, macrophages, anti-apoptotic genes
- MeSH terms
- Animals, Humans, Colorectal Neoplasms, Inflammatory Bowel Diseases, Interleukin-6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
